Single Dose Escalation Study of TR02 (Sustained Lipid Inhalation Technology [SLIT™] Amikacin) in Participants With Cystic Fibrosis (CF) Having Chronic Infections of Pseudomonas Aeruginosa
PHASE1CompletedINTERVENTIONAL
Enrollment
18
Participants
Timeline
Start Date
May 12, 2004
Primary Completion Date
February 8, 2005
Study Completion Date
February 8, 2005
Conditions
Cystic Fibrosis
Interventions
DRUG
SLIT™ Amikacin
Amikacin administered via the Pari LC STAR™ nebulizer.
DRUG
Placebo
Nebulized saline.
All Listed Sponsors
lead
Insmed Incorporated
INDUSTRY
NCT06238856 - Single Dose Escalation Study of TR02 (Sustained Lipid Inhalation Technology [SLIT™] Amikacin) in Participants With Cystic Fibrosis (CF) Having Chronic Infections of Pseudomonas Aeruginosa | Biotech Hunter | Biotech Hunter